AZ505: A Potent and Selective SMYD2 Inhibitor for Epigenetic and Cancer Biology Research

Executive Summary: AZ505 is a small molecule inhibitor that targets the protein lysine methyltransferase SMYD2 with high potency (IC50 = 0.12 μM) and selectivity (IC50 > 83.3 μM for related methyltransferases). It acts as a substrate-competitive inhibitor, blocking substrate binding but not S-adenosylmethionine (SAM) interaction. AZ505 has demonstrated efficacy in reducing SMYD2-mediated fibrosis and inflammation in preclinical models. Its use is supported by robust, peer-reviewed evidence and is primarily intended for research in epigenetic regulation and cancer biology, especially in models where SMYD2 is overexpressed (Chen et al., 2023). The product, available from APExBIO, is optimized for stability and solubility in experimental workflows.

Biological Rationale

SMYD2 (SET and MYND domain-containing 2) is a protein lysine methyltransferase that catalyzes methylation of histones H2B, H3, and H4, as well as non-histone substrates such as p53 and Rb (Chen et al., 2023). Methylation at specific lysine residues, notably H3K36, regulates gene transcription and chromatin state. Overexpression of SMYD2 has been observed in several cancers, including gastric cancer and esophageal squamous cell carcinoma (ESCC), and is implicated in tumorigenesis and progression (Chen et al., 2023). SMYD2 activity also contributes to pathological processes in chronic kidney disease (CKD), particularly in the promotion of renal fibrosis and inflammation through the Smad3 and STAT3 signaling pathways. Epigenetic modifications, such as histone methylation, are increasingly recognized as key regulators of gene expression in both health and disease (see also, KDM2A.com).

Mechanism of Action of AZ505, a potent and selective SMYD2 inhibitor

AZ505 is a small molecule that inhibits SMYD2 by occupying its peptide substrate binding groove, thereby preventing the methylation of both histone and non-histone substrates. It does not compete with the SMYD2 co-factor S-adenosylmethionine (SAM), distinguishing it as a substrate-competitive inhibitor. Quantitatively, AZ505 inhibits SMYD2 with an IC50 of 0.12 μM and a Ki of 0.3 μM (APExBIO product data). It shows high selectivity: the IC50 values for other methyltransferases such as SMYD3, DOT1L, and EZH2 are all above 83.3 μM, confirming minimal off-target activity (Chen et al., 2023). AZ505’s mechanism has been elucidated through structural and biochemical assays, including kinetic studies and crystallography.

Evidence & Benchmarks

• AZ505 inhibits SMYD2 enzymatic activity with an IC50 of 0.12 μM under standard in vitro conditions (25°C, pH 7.5, 1 hour) (APExBIO).
• In cisplatin-induced CKD mouse models, AZ505 significantly reduced renal fibrosis, suppressed epithelial-mesenchymal transition (EMT), and decreased inflammatory cytokine expression (Chen et al., 2023, DOI).
• AZ505 does not significantly inhibit SMYD3, DOT1L, or EZH2 at concentrations up to 83.3 μM (Chen et al., 2023, DOI).
• Cell-based assays demonstrate that AZ505 blocks methylation of p53 and Rb in cancer cell lines overexpressing SMYD2 (TCS359.com; see this article for lab protocol contrasts).
• AZ505’s efficacy and selectivity have been independently validated in multiple disease models, including renal fibrosis and gastric cancer (Chen et al., 2023, DOI).

Applications, Limits & Misconceptions

AZ505 is primarily used for research in epigenetic regulation, cancer biology, and disease modeling where SMYD2 activity is implicated. Its high selectivity allows for precise interrogation of SMYD2-mediated pathways without confounding effects from related methyltransferases. AZ505 has been used to study the role of SMYD2 in fibrosis, inflammation, and tumor suppressor regulation. However, its use is limited to in vitro and in vivo research and is not approved for diagnostic or therapeutic applications (APExBIO).

Common Pitfalls or Misconceptions

• AZ505 is not suitable for clinical or diagnostic use; it is for research purposes only.
• It may not be effective in systems where SMYD2 is not expressed or is not the primary methyltransferase driving the phenotype.
• The compound is not a pan-histone methyltransferase inhibitor; it shows minimal activity against SMYD3, DOT1L, and EZH2.
• Improper storage or handling (e.g., at temperatures above -20°C or insufficient solubilization in DMSO) can compromise compound stability and performance.
• Results obtained with AZ505 should be interpreted in the context of substrate-competitive inhibition, as it does not block SAM binding.

For a detailed workflow and benchmarking analysis, see Optimizing Epigenetic Assays with AZ505, which this article extends by providing updated evidence from fibrosis models and clarifying selectivity boundaries.

Workflow Integration & Parameters

AZ505, supplied by APExBIO (SKU B1255), is shipped as a solid and is soluble in DMSO. For stock solutions, dissolve AZ505 in DMSO, warming to 37°C and using ultrasonic shaking to enhance solubility. Store at -20°C for long-term stability. Typical working concentrations in cell-based assays range from 0.1 μM to 10 μM; optimization may be required for specific systems (product instructions). Experimental design should consider the substrate-competitive nature of AZ505, especially in co-factor excess conditions. For comprehensive benchmarking, see Nitrocefin.com—this article updates the translational relevance by integrating recent fibrosis data.

Conclusion & Outlook

AZ505 is a rigorously characterized, potent, and selective inhibitor of SMYD2, suitable for research in epigenetic regulation and disease modeling. Its substrate-competitive mechanism and high selectivity enable precise study of SMYD2-driven processes in cancer and fibrosis. As new data emerge on the role of SMYD2 in disease, AZ505 will remain a benchmark tool for mechanistic and translational studies. For the latest protocols and inter-study comparisons, researchers are encouraged to consult both the product page and recent peer-reviewed literature (Chen et al., 2023).